ArticleCell death discovery2026
Activation of methionine metabolism mediated by HNF4α confers ferroptosis resistance in hepatocellular carcinoma.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. Ferroptosis induction represents a promising therapeutic strategy, but its efficacy is constrained by tumor heterogeneity, particularly the relative resistance of epithelial cancer cells to ferroptosis inducers. In this study, we explore the mechanisms of epithelial HCC cells (EC) acquire resistance to ferroptosis. Transcriptomics and metabolomics analyses revealed that the cysteine and methionine metabolic pathway is associated with the resistance of EC to ferroptosis inducer imidazole ketone erastin (IKE). Cystine and methionine limitation experiments confirmed that the sensitivity of EC to IKE is related to methionine metabolism. Inhibiting the activity or expression of major methionine metabolic enzymes markedly enhanced the cell death and oxidative stress levels of EC. The analysis results of multiple public datasets indicate that the expression of the major methionine metabolic enzymes is related to hepatocyte nuclear factor 4α (HNF4α). Chromatin immunoprecipitation (ChIP) and luciferase assays were employed to confirm the transcriptional regulatory role of HNF4α on the major methionine metabolic enzymes. Additionally, in vitro RNA interference experiments and in vivo xenograft mouse models verified that down-regulation of HNF4α abolished ferroptosis resistance in EC. In conclusion, HNF4α-mediated activation of methionine metabolism sustains cellular antioxidant capacity, thereby promoting ferroptosis resistance in epithelial HCC cells. These findings position HNF4α and major methionine metabolic enzymes as potential therapeutic targets to overcome ferroptosis resistance in HCC, offering a rational basis for more effective treatment strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.